Morphic Holding Analyst Ratings
RBC Capital Maintains Morphic(MORF.US) With Hold Rating, Maintains Target Price $57
Analysts Have Conflicting Sentiments on These Healthcare Companies: Morphic Holding (MORF), Pyxis Oncology (PYXS) and Zynex (ZYXI)
Morphic Holding (MORF) Receives a Hold From RBC Capital
Morphic Holding Analyst Ratings
Stifel Nicolaus Keeps Their Hold Rating on Morphic Holding (MORF)
Jefferies Downgrades Morphic Holding to Hold From Buy, Price Target Is $57
Morphic Holding Buy Rating: High Acquisition Premium and Strategic Fit for Eli Lilly
Morphic Holding Analyst Ratings
Morphic Holding Acquisition Prospects: A Balanced Hold Rating Amid Lilly's Offer and Pipeline Potential
Morphic Holding (MORF) Was Downgraded to a Hold Rating at RBC Capital
Analysts Conflicted on These Healthcare Names: HilleVax, Inc (HLVX), UnitedHealth (UNH) and Morphic Holding (MORF)
Favorable Outlook for Eli Lilly's Acquisition of Morphic Holding With Strong Prospects for MORF-057
Morphic Holding (MORF) Was Downgraded to a Hold Rating at TD Cowen
Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN), Accolade (ACCD) and Morphic Holding (MORF)
Stifel Nicolaus Remains a Hold on Morphic Holding (MORF)
Morphic Holding (MORF) Gets a Buy From RBC Capital
Morphic Holding's Buy Rating Affirmed: Promising Trials and Strong Financial Outlook
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Morphic Holding (MORF)
Morphic Holding: A Strong Buy on Robust Financials and Promising Clinical Trials